EP 2626350 B1 20150415 - CYCLOPROPANE COMPOUND
Title (en)
CYCLOPROPANE COMPOUND
Title (de)
CYCLOPROPANVERBINDUNG
Title (fr)
COMPOSÉ DE CYCLOPROPANE
Publication
Application
Priority
- US 38534210 P 20100922
- JP 2010211629 A 20100922
- JP 2011071325 W 20110920
Abstract (en)
[origin: US2012095031A1] A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potential use for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: wherein Q represents —CH— or a nitrogen atom, R1a and R1b each independently represent a C1-6 alkyl group and the like, R1c represents a hydrogen atom and the like, R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group and the like, R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom and the like, and R3d represents a hydrogen atom and the like.
IPC 8 full level
C07D 401/12 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/538 (2006.01); A61P 1/14 (2006.01); A61P 3/10 (2006.01); A61P 11/00 (2006.01); A61P 13/08 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 25/34 (2006.01); A61P 25/36 (2006.01); C07D 239/34 (2006.01)
CPC (source: EP KR US)
A61K 31/506 (2013.01 - KR); A61P 1/00 (2017.12 - EP); A61P 1/14 (2017.12 - EP); A61P 3/00 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 13/00 (2017.12 - EP); A61P 13/08 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/20 (2017.12 - EP); A61P 25/22 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 25/34 (2017.12 - EP); A61P 25/36 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 239/34 (2013.01 - EP US); C07D 401/12 (2013.01 - EP KR US); C07D 417/12 (2013.01 - KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
US 2012095031 A1 20120419; US 8268848 B2 20120918; AR 083060 A1 20130130; AU 2011304285 A1 20130516; AU 2011304285 B2 20150129; BR 112013006594 A2 20160621; BR 112013006594 B1 20210817; CA 2811895 A1 20120329; CA 2811895 C 20151208; CL 2013000784 A1 20130705; CN 103153963 A 20130612; CN 103153963 B 20141224; DK 2626350 T3 20150629; EP 2626350 A1 20130814; EP 2626350 A4 20140212; EP 2626350 B1 20150415; ES 2540851 T3 20150714; IL 225437 A0 20130627; IL 225437 A 20150531; JO 2990 B1 20160905; JP 4944286 B1 20120530; JP WO2012039371 A1 20140203; KR 101458007 B1 20141104; KR 20130097776 A 20130903; MA 34609 B1 20131002; MX 2013003218 A 20130628; MY 160969 A 20170331; NZ 609313 A 20140530; PE 20131162 A1 20131019; PL 2626350 T3 20150831; PT 2626350 E 20150803; RS 54101 B1 20151030; RU 2013117464 A 20141027; RU 2571414 C2 20151220; SG 188585 A1 20130430; SI 2626350 T1 20150930; TW 201305129 A 20130201; TW I516484 B 20160111; UA 108510 C2 20150512; WO 2012039371 A1 20120329
DOCDB simple family (application)
US 201113237205 A 20110920; AR P110103428 A 20110920; AU 2011304285 A 20110920; BR 112013006594 A 20110920; CA 2811895 A 20110920; CL 2013000784 A 20130321; CN 201180045556 A 20110920; DK 11826816 T 20110920; EP 11826816 A 20110920; ES 11826816 T 20110920; IL 22543713 A 20130321; JO P20110289 A 20110920; JP 2011071325 W 20110920; JP 2012500752 A 20110920; KR 20137009631 A 20110920; MA 35823 A 20130412; MX 2013003218 A 20110920; MY PI2013000954 A 20110920; NZ 60931311 A 20110920; PE 2013000532 A 20110920; PL 11826816 T 20110920; PT 11826816 T 20110920; RS P20150418 A 20110920; RU 2013117464 A 20110920; SG 2013019880 A 20110920; SI 201130507 T 20110920; TW 100133754 A 20110920; UA A201304939 A 20110920